Fabentech receives Marke0ng Authoriza0on for Ricimed®

• First Marke+ng Authoriza+on granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and poten+ally fatal ricin intoxica+ons.
• Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transi+on to a new scale and, with recent support from the European HERA Invest program, reinforces its posi+oning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets.

Read the press release